David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille, Marseille, APHM

Por um escritor misterioso
Last updated 20 setembro 2024
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille,  Marseille, APHM
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille,  Marseille, APHM
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille,  Marseille, APHM
Abstract Book - PDF - San Antonio Breast Cancer Symposium
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille,  Marseille, APHM
Efficacité de l'hydroxychloroquine et de l'azithromycine
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille,  Marseille, APHM
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille,  Marseille, APHM
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19, Genome Medicine
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille,  Marseille, APHM
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille, Marseille, APHM
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille,  Marseille, APHM
PDF) Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille,  Marseille, APHM
APHM (Assistance Publique - Hopitaux de Marseille) sur LinkedIn : #sensibilisation #prévention #sécuritéenmer
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille,  Marseille, APHM
session
David LAGIER, MD PhD, Assistance Publique Hôpitaux de Marseille,  Marseille, APHM
PDF) X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

© 2014-2024 likytut.eu. All rights reserved.